Project information
CZ-OPENSCREEN: National Infrastructure for Chemical Biology
(CZ-OPENSCREEN)
- Project Identification
- LM2018130
- Project Period
- 1/2020 - 12/2022
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Large Infrastructures for Research, Development and Innovation
- MU Faculty or unit
- Faculty of Science
- Cooperating Organization
-
Institute of Molecular Genetics of the ASCR, v. v. i.
- Responsible person RNDr. Petr Bartůněk, CSc.
Prague Institute of Chemical Technology
The aim of the project „CZ-‐OPENSCREEN: National infrastructure for chemical biology” is to operate the state-‐of-‐the-‐art infrastructure for basic and applied research in the fields of chemical biology and genetics and provide Open Access to users. It will serve as the National node of the pan-European ESFRI infrastructure EU-‐OPENSCREEN, providing trans-‐national access to the Screening platform and to the European Chemical Biology Library. The mission of CZ-‐OPENSREEN is to identify new molecular probes/tools for research and new potential therapeutics.
Publications
Total number of publications: 22
2022
-
Substituted aminothiazoles as inhibitors of nucleases
Publisher: IP Australia, state: Australia, patent's number: AU2019256670, year: 2022
-
Substituted propanamides as inhibitors of nucleases
Publisher: United States Patent and Trademark Office, state: United States of America, patent's number: US11453663, year: 2022
-
Substituted propanamides as inhibitors of nucleases
Publisher: IP Australia, state: Australia, patent's number: AU2019256672, year: 2022
-
Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides
Journal of Medicinal Chemistry, year: 2022, volume: 65, edition: 7, DOI
-
ヌクレアーゼの阻害剤としての置換アミノチアゾール
Publisher: Japan Patent Office (JPO), state: Japan, patent's number: JP7175031, year: 2022
-
ヌクレアーゼの阻害剤としての置換プロパンアミド
Publisher: Japan Patent office, state: Japan, patent's number: JP7148999, year: 2022
-
백혈병, 림프종 및 고형 종양의 치료에 사용하기 위한 4-(1H-이미다졸-5-일)-1H-피롤로[2,3-b]피리딘
Publisher: Korean Intellectual Property Office, state: Korea, Republic of, patent's number: KR10-2465111, year: 2022
-
白血病、リンパ腫および固形腫瘍の治療に使用するための４－（１Ｈ－イミダゾール－５－イル）－１Ｈ－ピロロ［２，３－ｂ］ピリジン
Publisher: Japan Patent Office, state: Japan, patent's number: JP7008967, year: 2022
2021
-
4—(1h— imidazol— 5— yl) -1h-pyrrolo (2, 3-b) pyridines for use in the treatment of leukaemias, lymphomas and solid tumors
Publisher: The Australian Patents Register, state: Australia, patent's number: AU 2019246220, year: 2021
-
Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core
European Journal of Medicinal Chemistry, year: 2021, volume: 215, edition: April, DOI